Seres Therapeutics, Inc.
MCRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -189.72 | 0.51 | 0.58 | -0.01 |
| FCF Yield | -5.77% | -3.50% | -1.97% | -0.38% |
| EV / EBITDA | -23.80 | -38.92 | -50.96 | -11.16 |
| Quality | ||||
| ROIC | -104.64% | -39.67% | -93.59% | -21.16% |
| Gross Margin | 0.00% | 99.44% | 85.91% | 100.00% |
| Cash Conversion Ratio | -1,092.71 | 1.03 | 0.91 | -0.10 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 61.35% |
| Free Cash Flow Growth | -18.88% | 47.48% | -8,191.77% | 96.94% |
| Safety | ||||
| Net Debt / EBITDA | -0.55 | -0.91 | 0.00 | 2.31 |
| Interest Coverage | 0.00 | -8.20 | -40.95 | -22.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.02 | 0.00 | 0.00 |
| Cash Conversion Cycle | -101.30 | 13,508.29 | -6,340.24 | -35.33 |